Position
Fidelity in Crescent Biopharma, Inc.
Back to the book · All holders of CBIO
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$1.53M$18.37 → $18.00
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 4.13M | $49M | — | — | — | 0.0% |
| Q1 2026 | 4.13M | $75.9M | $18.37 | $26.9M | $0 | 0.0% |
| Q2 2026 | 4.13M | $74.4M | $18.00 | −$1.53M | −$0 | 0.0% |